Lifeward Ltd. has announced that it received its first prior authorization approval from a UnitedHealthcare Medicare Advantage Plan for the ReWalk 7 Personal Exoskeleton. This marks a significant step forward in expanding reimbursement pathways and accelerating access to advanced exoskeleton technology for individuals with spinal cord injuries. The approval follows the Centers for Medicare & Medicaid Services' 2024 implementation of a reimbursement pathway for personal exoskeletons. Lifeward reports an increase in prior authorizations as more payers adopt coverage, improving predictability and access for beneficiaries. No other organizations were mentioned as recipients of this approval.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9576987-en) on November 17, 2025, and is solely responsible for the information contained therein.